A L Harris

Summary

Affiliation: Imperial Cancer Research Fund
Country: UK

Publications

  1. pmc The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer
    K J Turner
    ICRF Molecular Oncology Laboratory and Angiogenesis Group, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK
    Br J Cancer 86:1276-82. 2002
  2. pmc Hypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesis
    H J Knowles
    ICRF Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Breast Cancer Res 3:318-22. 2001
  3. ncbi Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy
    A L Harris
    Imperial Cancer Research Fund, Molecular Oncology Laboratories, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom
    Clin Cancer Res 7:1992-7. 2001
  4. ncbi von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy
    A L Harris
    Imperial Cancer Research Fund, Medical Oncology Laboratories, University of Oxford, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, England
    Oncologist 5:32-6. 2000
  5. pmc The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy
    E Y Tan
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
    Br J Cancer 100:405-11. 2009
  6. pmc The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo
    H T Zhang
    Molecular Angiogenesis Laboratory, Imperial Cancer Research Fund, Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, UK
    Br J Cancer 83:63-8. 2000
  7. ncbi Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway
    C Blancher
    Imperial Cancer Research Fund, Molecular Oncology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom
    Cancer Res 61:7349-55. 2001
  8. ncbi Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: expression of VEGF in the human endometrium
    L Zhang
    Imperial Cancer Research Fund, Institute of Molecular Medicine, University of Oxford, U K
    J Pathol 185:402-8. 1998
  9. ncbi Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines
    C Blancher
    Imperial Cancer Research Fund, Molecular Oncology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    Cancer Res 60:7106-13. 2000
  10. pmc Up-regulation of macrophage wnt gene expression in adenoma-carcinoma progression of human colorectal cancer
    K Smith
    ICRF Molecular Oncology Laboratory, John Radcliffe Hospital, Oxford, UK
    Br J Cancer 81:496-502. 1999

Collaborators

Detail Information

Publications90

  1. pmc The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer
    K J Turner
    ICRF Molecular Oncology Laboratory and Angiogenesis Group, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK
    Br J Cancer 86:1276-82. 2002
    ..The expression of CA IX on the luminal surface justifies investigation of its utility as a therapeutic target/prognostic indicator...
  2. pmc Hypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesis
    H J Knowles
    ICRF Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Breast Cancer Res 3:318-22. 2001
    ..Complex interactions between tumour cell and macrophage hypoxia-regulated gene products and their associated pathways form the basis for the hypoxic promotion of tumourigenesis and malignant progression...
  3. ncbi Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy
    A L Harris
    Imperial Cancer Research Fund, Molecular Oncology Laboratories, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom
    Clin Cancer Res 7:1992-7. 2001
    ..05) and improved survival (P = 0.04). The soluble receptors measured weeks before response were assessed and correlated with response and survival, showing they may be useful to monitor and develop antiangiogenic therapy...
  4. ncbi von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy
    A L Harris
    Imperial Cancer Research Fund, Medical Oncology Laboratories, University of Oxford, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, England
    Oncologist 5:32-6. 2000
    ..Data obtained from monitoring these patients will provide valuable information for adjuvant treatment trials in cancer patients...
  5. pmc The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy
    E Y Tan
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
    Br J Cancer 100:405-11. 2009
    ....
  6. pmc The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo
    H T Zhang
    Molecular Angiogenesis Laboratory, Imperial Cancer Research Fund, Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, UK
    Br J Cancer 83:63-8. 2000
    ..This is probably due to the ability of the 121 isoform, unlike the 165 and 189 isoforms, to freely diffuse from the cells producing it...
  7. ncbi Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway
    C Blancher
    Imperial Cancer Research Fund, Molecular Oncology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom
    Cancer Res 61:7349-55. 2001
    ..These results have implications for the use of PI3K inhibitors to inhibit synergistic effects of hypoxia with a wide range of common oncogenes...
  8. ncbi Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: expression of VEGF in the human endometrium
    L Zhang
    Imperial Cancer Research Fund, Institute of Molecular Medicine, University of Oxford, U K
    J Pathol 185:402-8. 1998
    ..This study has shown that the commercially available anti-VEGF monoclonal antibody M293 is excellent for the immunohistochemical localization of VEGF in paraffin sections...
  9. ncbi Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines
    C Blancher
    Imperial Cancer Research Fund, Molecular Oncology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    Cancer Res 60:7106-13. 2000
    ..A balance between the angiogenic and tumor-inhibiting levels of HIF proteins may, therefore, be necessary for optimal tumor growth...
  10. pmc Up-regulation of macrophage wnt gene expression in adenoma-carcinoma progression of human colorectal cancer
    K Smith
    ICRF Molecular Oncology Laboratory, John Radcliffe Hospital, Oxford, UK
    Br J Cancer 81:496-502. 1999
    ..These results show a major difference in wnt expression in colon cancer compared to colon adenomas and suggest stromal wnt expression may play a role in tumour progression...
  11. ncbi Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines
    A Jones
    Molecular Oncology Unit, Imperial Cancer Research Fund, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK
    Clin Cancer Res 7:1263-72. 2001
    ..These results suggest that components of the hypoxia response pathway, including HIF-1 alpha and HIF-2 alpha, are important cofactors in the regulation of VEGF in bladder cancer and are therapeutic targets in this disease...
  12. ncbi Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha
    M S Wiesener
    Institute of Molecular Medicine and the Department of Cellular Science, John Radcliffe Hospital, Oxford, UK
    Blood 92:2260-8. 1998
    ....
  13. pmc Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E
    P A Scott
    Imperial Cancer Research Fund, Institute of Molecular Medicine, John Radcliffe, Oxford, UK
    Br J Cancer 77:2120-8. 1998
    ..VEGF expression is also significantly associated with factors correlating with a poor outcome, implying a role in progression of this disease...
  14. ncbi Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1
    H Turley
    University Department of Cellular Science, University of Oxford, John Radcliffe Hospital, U K
    J Pathol 186:313-8. 1998
    ..This should be a useful and reliable reagent for studies of VEGF and angiogenesis in human pathological material...
  15. pmc The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium
    S B Fox
    Department of Cellular Science, University of Oxford, John Radcliffe Hospital, UK
    Br J Cancer 73:275-80. 1996
    ..05) but not in other patient groups. This might be due to the potentiation of chemotherapeutic agents like methotrexate by TP. Therefore, this enzyme might be a prediction marker for response to chemotherapy...
  16. ncbi HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors
    H M Sowter
    Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, United Kingdom
    Cancer Res 61:6669-73. 2001
    ..This study shows that genes regulating cell death can be hypoxically induced and are overexpressed in clinical tumors...
  17. pmc Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines
    S Houlbrook
    Molecular Oncology Laboratories, Imperial Cancer Research Fund, John Radcliffe Hospital, Oxford, UK
    Br J Cancer 72:1454-61. 1995
    ..No relationship was found between the level of mRNA for topoisomerase II alpha or beta, and either sensitivity of breast cancer cell lines to topoisomerase II inhibitors or the level of topoisomerase II protein expression...
  18. pmc Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites
    J Kirk
    ICRF Laboratory, John Radcliffe Hospital, Headington, Oxford, UK
    Br J Cancer 67:1189-95. 1993
    ..Toremifene and tamoxifen would therefore appear to be good candidates for in vivo studies as MDR modulating agents in selected patients with P-glycoprotein-positive tumours...
  19. ncbi Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF
    S B Fox
    Department of Cellular Science, University of Oxford, John Radcliffe Hospital, UK
    Ann Oncol 8:271-5. 1997
    ..High expression of TP in cell lines potentiates the effects of the cytotoxic drugs 5-fluorouracil and methotrexate, both of which are used in the cyclophosphamide, 5-fluorouracil and methotrexate (CMF) treatment regimen of breast cancer...
  20. ncbi Vascular endothelial growth factor transgenic mice exhibit reduced male fertility and placental rejection
    L Huminiecki
    Molecular Angiogenesis Laboratory, Imperial Cancer Research Fund, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Mol Hum Reprod 7:255-64. 2001
    ..The muc1-VEGF (121 isoform) transgenic mouse provides an animal model with which to further study this VEGF-induced pathology...
  21. pmc The transcription factor DEC1 (stra13, SHARP2) is associated with the hypoxic response and high tumour grade in human breast cancers
    J Chakrabarti
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford OX3 9DU, UK
    Br J Cancer 91:954-8. 2004
    ..Reversing this phenotype may alter the biological behaviour of individual tumours...
  22. pmc Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway
    K Clarke
    Growth Factor Group, Molecular Oncology Laboratories, Imperial Cancer Research Fund, John Radcliffe Hospital, Oxford, OX3 9DU, UK
    Br J Cancer 84:1322-9. 2001
    ....
  23. pmc Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase
    A V Patterson
    ICRF Clinical Oncology Unit, University of Oxford, John Radcliffe Hospital, UK
    Br J Cancer 72:669-75. 1995
    ..These results confirm that dThdPase is a major pathway in the metabolic activation of 5'-DFUR, and the bystander effect suggests that this may be a suitable enzyme for gene therapy-directed enzyme/prodrug activation therapy...
  24. pmc Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast
    C C Wykoff
    Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    Am J Pathol 158:1011-9. 2001
    ..The existence of differential regulation and associations with an aggressive phenotype may be important in the development of selective inhibitors of CAs, because the latter have recently been shown to prevent tumor invasion...
  25. pmc Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression
    J P Crew
    The Molecular Angiogenesis Group, Imperial Cancer Research Fund, The Institute of Molecular Medicine, Oxford, UK
    Br J Cancer 82:161-6. 2000
    ..04, Cox proportional hazards model). The study demonstrates that eIF-4E may be involved in translational regulation of VEGF in bladder cancer and might have a role as a prognostic factor in bladder cancer...
  26. pmc bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer
    R D Leek
    Imperial Cancer Research Fund, University of Oxford, John Radcliffe Hospital, UK
    Br J Cancer 69:135-9. 1994
    ..Thus, loss of bcl-2 expression in breast cancer is associated with a range of molecular markers of poor prognosis and may define part of an ER-negative, EGFR-positive phenotype...
  27. pmc The influence of high dose hydroxyurea on the incorporation of 5-iodo-2-deoxyuridine (IUdR) by human bone marrow and tumour cells in vivo
    P A Philip
    Imperial Cancer Research Fund, Clinical Oncology Unit, Churchill Hospital, Oxford, UK
    Br J Cancer 67:644-9. 1993
    ....
  28. pmc Selective toxicity of TGF-alpha-PE40 to EGFR-positive cell lines: selective protection of low EGFR-expressing cell lines by EGF
    J Kirk
    ICRF Laboratories, Institute of Molecular Medicine, Headington, UK
    Br J Cancer 69:988-94. 1994
    ....
  29. pmc cDNA transfection followed by the isolation of a MCF-7 breast cell line resistant to tamoxifen in vitro and in vivo
    M Toi
    Molecular Oncology Laboratory, Imperial Cancer Research Fund, University of Oxford, John Radcliffe Hospital, UK
    Br J Cancer 68:1088-96. 1993
    ..Preliminary results suggest that an autocrine growth stimulatory mechanism may be one pathway of such resistance...
  30. pmc Loss of interleukin 4 receptor-associated molecule gp200-MR6 in human breast cancer: prognostic significance
    L Kaklamanis
    Department of Cellular Science, John Radcliffe Hospital, Oxford, UK
    Br J Cancer 74:1627-31. 1996
    ..Evidence of down-regulation of the gp200-MR6 molecule has implications for IL-4-linked toxin therapy and, as IL-4 is an inhibitor of breast epithelial growth, may represent loss of a tumour-suppression mechanism...
  31. pmc Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion
    C Fujiyama
    Molecular Oncology Unit, ICRF, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK
    Br J Cancer 84:558-64. 2001
    ..In conclusion, this model shows the urokinase system is important for bladder invasion and can be used to investigate other mechanisms of bladder cancer invasion and also for the testing of intravesical drugs...
  32. pmc The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues
    H Turley
    Department of Cellular Science, University of Oxford, John Radcliffe Hospital, UK
    Br J Cancer 75:1340-6. 1997
    ..The apparent up-regulation of topoisomerase IIbeta in neoplastic cells has implications for the response of patients to anti-tumour therapies that include topoisomerase II-targeting drugs...
  33. pmc Differential expression of the topoisomerase II alpha and beta genes in human breast cancers
    M I Sandri
    Imperial Cancer Research Fund, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Br J Cancer 73:1518-24. 1996
    ....
  34. pmc Human AP endonuclease 1 (HAP1) protein expression in breast cancer correlates with lymph node status and angiogenesis
    S Kakolyris
    Department of Cellular Science, John Radcliffe Hospital, University of Oxford, UK
    Br J Cancer 77:1169-73. 1998
    ....
  35. pmc Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer
    C Blick
    Molecular Oncology Laboratories, The Weatherall Institute of Molecular Medicine, The University of Oxford, John Radcliffe Hospital, OX3 9DS Oxford, UK
    Br J Cancer 109:50-9. 2013
    ..In this study, we investigated the effects of hypoxia on miR-100 and FGFR3 expression, and the link between miR-100 and FGFR3 in hypoxia...
  36. ncbi Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study
    S B Fox
    Department of Cellular Science, John Radcliffe Hospital, University of Oxford, U K
    J Pathol 176:183-90. 1995
    ..The high expression present in macrophages and skin might be important for total body thymidine homeostasis...
  37. pmc Thymidine phosphorylase is angiogenic and promotes tumor growth
    A Moghaddam
    Imperial Cancer Research Fund, Institute of Molecular Medicine, Oxford, United Kingdom
    Proc Natl Acad Sci U S A 92:998-1002. 1995
    ..These data and the correlation of expression in tumors with malignancy identify TP as a target for antitumor strategies...
  38. pmc The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages
    K L Talks
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, United Kingdom
    Am J Pathol 157:411-21. 2000
    ..In contrast, in normal tissue neither molecule was detectable except within subsets of bone marrow macrophages, where HIF-2alpha was strongly expressed...
  39. ncbi Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer
    A Giatromanolaki
    Department of Cellular Science, John Radcliffe Hospital, Oxford, U K
    J Pathol 181:196-9. 1997
    ..The present study provides a baseline for future studies in non-small cell lung cancer to correlate PD-ECGF expression with tumour vascularization, prognosis, and response to chemotherapy...
  40. pmc Cid1, a fission yeast protein required for S-M checkpoint control when DNA polymerase delta or epsilon is inactivated
    S W Wang
    Imperial Cancer Research Fund Molecular Oncology Laboratory, University of Oxford Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom
    Mol Cell Biol 20:3234-44. 2000
    ..Genetic data suggest that Cid1 acts in association with Crb2/Rhp9 and through the checkpoint-signaling kinase Chk1 to inhibit unscheduled mitosis specifically when DNA polymerase delta or epsilon is inhibited...
  41. doi Regulation of autophagy by ATF4 in response to severe hypoxia
    T Rzymski
    Growth Factor Group, Cancer Research UK, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
    Oncogene 29:4424-35. 2010
    ..In summary, we show that ATF4 has a key role in the regulation of autophagy in response to ER stress and provide a direct mechanistic link between the UPR and the autophagic machinery...
  42. ncbi Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival
    K Smith
    ICRF Molecular Oncology Laboratory, John Radcliffe Hospital, Oxford, UK
    Ann Oncol 10:707-13. 1999
    ..The angiogenic factor, basic fibroblast growth factor (bFGF), has been associated with tumourigenesis and metastasis in several human cancers. There are few quantitative studies of bFGF expression in normal tissues compared to cancer...
  43. ncbi Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer
    A Jones
    Molecular Oncology Unit, ICRF, Institute of Molecular Medicine, Oxford, UK
    BJU Int 85:276-80. 2000
    ..Forty-eight patients had a histopathological diagnosis of prostate cancer (16 local disease, 32 metastatic), nine had benign prostatic hyperplasia (BPH) and 21 were healthy controls...
  44. pmc A phase II study of bryostatin 1 in metastatic malignant melanoma
    D J Propper
    ICRF Medical Oncology Unit, Churchill Hospital, Headington, Oxford, UK
    Br J Cancer 78:1337-41. 1998
    ..In conclusion, single-agent bryostatin appears ineffective in the treatment of metastatic melanoma in patients previously treated with chemotherapy. It should, however, be investigated further in previously untreated patients...
  45. pmc Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer
    A M Jubb
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
    Br J Cancer 101:1749-57. 2009
    ..The aim of this study was to characterise the expression of Dll4 in colon cancer and to assess whether it is associated with markers of hypoxia and prognosis...
  46. pmc The ubiquitin-proteasome pathway in cancer
    V Spataro
    Imperial Cancer Research Fund, University of Oxford, Institute of Molecular Medicine, The John Radcliffe, UK
    Br J Cancer 77:448-55. 1998
    ....
  47. pmc Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer
    P Korkolopoulou
    University Department of Cellular Science, John Radcliffe Hospital, University of Oxford, UK
    Br J Cancer 73:148-53. 1996
    ..However, the immunophenotypic profile of MHC class I and TAP-1 seems to be unrelated in vivo to the phenotype, growth or survival of NSCLC...
  48. ncbi The expression and cellular localization of phosphorylated VEGFR2 in lymphoma and non-neoplastic lymphadenopathy: an immunohistochemical study
    G Pillai
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, UK
    Histopathology 46:209-16. 2005
    ..To study the expression of phosphorylated vascular endothelial growth factor receptor 2 (VEGFR2), a membrane-bound tyrosine kinase receptor to vascular endothelial growth factor, in lymphoma and non-neoplastic lymphadenopathy...
  49. ncbi Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers
    T S O'Brien
    Molecular Angiogenesis Group, Imperial Cancer Research Rund, University of Oxford, United Kingdom
    Cancer Res 56:4799-804. 1996
    ..94). TP protein is expressed in bladder cancers, and expression is associated with an aggressive phenotype. Because TP can activate a number of cytotoxic agents, it provides a potential therapeutic target in bladder cancer...
  50. ncbi The HIF pathway: implications for patterns of gene expression in cancer
    C C Wykoff
    Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Novartis Found Symp 240:212-25; discussion 225-31. 2001
    ..Equally regulation of the HIF-1alpha/pVHL interaction in normal cells should provide insights into the physiological mechanisms operating in cellular oxygen sensing...
  51. pmc Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer
    N Dobbs
    Imperial Cancer Research Fund Medical Oncology Unit, Churchill Hospital, Oxford, UK
    Br J Cancer 79:1413-8. 1999
    ..Encouraging preclinical anti-tumour activity and the favourable toxicity profile in patients suggest the merit of future studies combining RC-160 with anti-oestrogen, cytotoxic and anti-angiogenic agents...
  52. pmc Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma
    N S Brown
    Molecular Angiogenesis Group, Cancer Research UK, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Br J Cancer 92:1696-701. 2005
    ..Administration of the antioxidant N-acetylcysteine together with a blocking anti-VEGF antibody abrogates the increase in tumorigenicity. Our results support the increased efficacy of combination approaches to antiangiogenic therapy...
  53. doi Quantification of circulating cell-free plasma DNA and endothelial gene RNA in patients with burns and relation to acute thermal injury
    A Fox
    Stem Cells and Immunotherapies Laboratory, NHS Blood and Transplant Service, Oxford, UK
    Burns 34:809-16. 2008
    ..Raised levels of cell-free nucleic acids have been detected in various pathological processes including burns. We quantified circulating nucleic acids as potential objective measures of burn severity with predictive and prognostic value...
  54. doi Multiple pathways are involved in the anoxia response of SKIP3 including HuR-regulated RNA stability, NF-kappaB and ATF4
    T Rzymski
    Molecular Oncology Laboratories, Cancer Research UK, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Oncogene 27:4532-43. 2008
    ..Thus, the response to anoxia is mediated by three pathways independently of HIF, suggesting that combined therapeutic approaches would be needed to maximize effects against this pathway...
  55. pmc Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39
    S Kakolyris
    Department of Cellular Science, University of Oxford, UK
    Br J Cancer 82:844-51. 2000
    ..The VMI identifies a subset of patients who have a high chance of regional node involvement...
  56. pmc Expression and hormone regulation of Wnt2, 3, 4, 5a, 7a, 7b and 10b in normal human endometrium and endometrial carcinoma
    T D Bui
    Molecular Oncology Laboratory, University of Oxford, John Radcliffe Hospital, Headington, UK
    Br J Cancer 75:1131-6. 1997
    ....
  57. ncbi cDNA cloning of a human dishevelled DVL-3 gene, mapping to 3q27, and expression in human breast and colon carcinomas
    T D Bui
    Imperial Cancer Research Fund, University of Oxford, Headington, Oxford, United Kingdom
    Biochem Biophys Res Commun 239:510-6. 1997
    ..The data indicates that DVL-3 is widely expressed in human cells and supports the notion of a new developmental gene family for dishevelled which may have a widespread role in signal transduction...
  58. pmc High expression of Wnt7b in human superficial bladder cancer vs invasive bladder cancer
    T D Bui
    Imperial Cancer Research Fund, University of Oxford, Institute of Molecular Medicine, John Radcliffe Hospital, UK
    Br J Cancer 77:319-24. 1998
    ..2). The differential expression of Wnt7b suggests a role in the early events of superficial bladder tumorigenesis involving cell adhesion and provides further evidence of different pathways of evolution of superficial and invasive cancer...
  59. pmc Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer
    D J Propper
    ICRF Medical Oncology Unit, Churchill Hospital, Headington, Oxford, UK
    Br J Cancer 82:1776-82. 2000
    ..However, BW12C in combination with MMC for 5-FU-resistant colorectal cancer is not an effective regimen. This could be related to drug resistance rather than a failure to enhance cytotoxicity...
  60. pmc Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors
    S L Davies
    Imperial Cancer Research Fund Laboratories, University of Oxford, UK
    Br J Cancer 75:816-21. 1997
    ..The evidence presented here suggests that topo IIalpha, not topo IIbeta, is more likely to be the major in vivo target for ICRF-159...
  61. ncbi Isolation of a full-length human WNT7A gene implicated in limb development and cell transformation, and mapping to chromosome 3p25
    T D Bui
    Imperial Cancer Research Fund, Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, UK
    Gene 189:25-9. 1997
    ..It possessed the 22 conserved cysteine residues and 3 more at the amino terminus, and a putative poly A tail. This is the fifth human WNT gene in which a complete cDNA sequence had been determined...
  62. ncbi Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis
    A Jones
    Molecular Oncology Unit, ICRF, Institute of Molecular Medicine, Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, UK
    BJU Int 86:80-6. 2000
    ..To determine whether angiogenesis can be used as an additional prognostic indicator in patients with stage 1 germ cell tumours of the testis...
  63. ncbi Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues
    E J Soilleux
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, UK
    Histopathology 47:602-10. 2005
    ..In this study, we raised and characterized monoclonal antibodies against PHD-1, PHD-2, PHD-3 and FIH...
  64. pmc PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer
    S M Wigfield
    Cancer Research UK, Growth Factor Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Headington, Oxford OX3 9DU, UK
    Br J Cancer 98:1975-84. 2008
    ..005 split by median). These results indicate that HIF regulation of PDK-1 has a key role in maintaining lactate production in human cancer and that the investigation of PDK-1 inhibitors should be investigated for antitumour effects...
  65. ncbi Hypoxia-induced pathways in breast cancer
    T I Goonewardene
    Imperial Cancer Research Fund, Molecular Oncology Laboratory, University of Oxford, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Microsc Res Tech 59:41-8. 2002
    ....
  66. pmc Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer
    J J Ord
    Department of Urology, Churchill Hospital, Oxford, UK
    Br J Cancer 93:346-54. 2005
    ..01). This study defines genes suitable for an in vivo hypoxia 'profile', shows the heterogeneity of the hypoxia response and describes new hypoxia-regulated genes...
  67. pmc Interleukin-4 receptor and epidermal growth factor receptor expression in colorectal cancer
    L Kaklamanis
    Nuffield Department of Pathology, John Radcliffe Hospital, Headington, Oxford, UK
    Br J Cancer 66:712-6. 1992
    ..All but one of the EGFR positive malignant tumours showed coexpression of IL-4 receptor. Lymph node involvement by tumour cells was detected in 25 out of 45 patients. Eighteen of these 25 cases were positive with EGFR1...
  68. pmc Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast
    R D Leek
    ICRF Molecular Oncology Laboratory, University of Oxford, Institute of Molecular Medicine, John Radcliffe Hospital, UK
    Br J Cancer 79:991-5. 1999
    ..This, in turn, may attract macrophages into the tumour, which then contribute to the angiogenic process, giving rise to an association between high levels of angiogenesis and extensive necrosis...
  69. ncbi Detection of mammaglobin mRNA in the plasma of breast cancer patients
    S Gal
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Headington, United Kingdom
    Ann N Y Acad Sci 945:192-4. 2001
    ..We aimed to detect cell-free mammaglobin mRNA in the plasma of breast cancer patients and to investigate whether it can be used as a marker for diagnosis of breast cancer...
  70. pmc Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
    G Deplanque
    University of Oxford, Cancer Research UK Medical Oncology Unit, The Churchill, Old Road, Oxford OX3 7LJ, England
    Br J Cancer 91:1645-50. 2004
    ..IM862 should not be further evaluated as a single agent at these doses and schedule for this population of patients. The decrease in VEGF levels warrants further investigation of IM862 as an antiangiogenic therapy...
  71. pmc Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha
    J P Braybrooke
    ICRF Medical Oncology Unit, Churchill Hospital, Oxford, UK
    Br J Cancer 83:219-24. 2000
    ....
  72. pmc Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine
    D J Propper
    ICRF Medical Oncology Unit, Churchill Hospital, Headington, Oxford, UK
    Br J Cancer 82:1759-63. 2000
    ..There were responses in patients not directly switched from DTIC to DBPT, suggesting combination therapy may be of value in a small subgroup of melanoma patients...
  73. ncbi Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer. association with prognosis
    Z E Winters
    Imperial Cancer Research Fund Molecular Oncology Laboratory, University of Oxford Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Eur J Cancer 37:2405-12. 2001
    ..Investigation of the subcellular distribution of cell cycle regulatory proteins, particularly p21(WAF1/CIP1), could provide valuable prognostic markers in breast cancer...
  74. pmc Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma
    R D Leek
    Imperial Cancer Research Fund Molecular Oncology Laboratory, University of Oxford, Institute of Molecular Medicine, John Radcliffe Hospital, UK
    Br J Cancer 77:2246-51. 1998
    ....
  75. pmc A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions
    P S Braddock
    Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, UK
    Br J Cancer 69:890-8. 1994
    ..These observations could substantially widen the anti-tumour therapeutic opportunities for this class of compound...
  76. pmc Bcl-2 protein expression: association with p53 and prognosis in colorectal cancer
    L Kaklamanis
    University Department of Cellular Science, John Radcliffe Hospital, University of Oxford, UK
    Br J Cancer 77:1864-9. 1998
    ..The bcl-2(+)/p53(-) phenotype is similar to that of normal mucosa, and these results suggest that such cases represent an indolent group at an early stage in the progression of colorectal cancer...
  77. pmc Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer
    C P S Potter
    Cancer Research UKGrowth Factor Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Br J Cancer 89:2-7. 2003
    ..Inhibitors of CA may inhibit tumour growth and invasion, with consequent therapeutic potential...
  78. pmc The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis
    H E Gee
    Molecular Oncology Laboratories, Department of Oncology, University of Oxford, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Br J Cancer 104:1168-77. 2011
    ..To investigate small-nucleolar RNAs (snoRNAs) as reference genes when measuring miRNA expression in tumour samples, given emerging evidence for their role in cancer...
  79. doi Hypoxia-driven cell motility reflects the interplay between JMY and HIF-1α
    A S Coutts
    Laboratory of Cancer Biology, Department of Oncology, University of Oxford, Oxon, UK
    Oncogene 30:4835-42. 2011
    ..Our results establish the interplay between JMY and HIF-1α as a new mechanism that controls cell motility under hypoxic stress...
  80. pmc Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene
    F M Buffa
    Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK
    Br J Cancer 102:428-35. 2010
    ..Hypoxia is a key factor promoting solid tumour progression and resistance to therapy; a hypoxia signature has the potential to be not only prognostic but also to predict benefit from particular interventions...
  81. pmc Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene
    C C Wykoff
    Molecular Oncology Laboratories, John Radcliffe Hospital, Weatherall Institute of Molecular Medicine, Cancer Research UK, Oxford OX3 9DS, UK
    Br J Cancer 90:1235-43. 2004
    ..Hypoxia induced downregulation of Cyclin D1 in nonrenal cells via an HIF independent pathway. The selective regulation of Cyclin D1 by hypoxia in renal cells may therefore contribute to the tissue selectivity of VHL mutation...
  82. ncbi Hypoxia and anaemia in head and neck squamous cell carcinoma - mechanisms of therapy failure and provision of new therapeutic targets
    S C A Winter
    Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Clin Otolaryngol 30:99-104. 2005
  83. ncbi Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer
    A L Bacon
    Laboratory of Molecular Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Cancer Research UK, Oxford, UK
    Oncogene 26:132-41. 2007
    ..These data suggest that BNIP3 plays an important role in hypoxic cell death and epigenetic mechanisms selectively silence its expression in CRC...
  84. ncbi Mechanisms of multidrug resistance in cancer treatment
    A L Harris
    Molecular Oncology Laboratory, University of Oxford, John Radcliffe Hospital, Headington, UK
    Acta Oncol 31:205-13. 1992
    ..g. A45. 5) Drug activation. Mitomycin C as well as cyclophosphamide and VP16 require activation for their effects. Low levels of cytochrome p450 reductase are associated with MMC resistance...
  85. doi An oncogenic role of eIF3e/INT6 in human breast cancer
    M Grzmil
    Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
    Oncogene 29:4080-9. 2010
    ..Taken together, our study data suggest that eIF3e has a positive role in breast cancer progression. It regulates the translation, and in some cases abundance, of mRNAs involved in key aspects of cancer cell biology...
  86. doi The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses
    H E Campbell
    Health Economics Research Centre, University of Oxford, Headington, Oxford, United Kingdom
    Eur J Cancer 47:2517-30. 2011
    ..These adjuvant chemotherapy regimens were used in three large UK-led randomised controlled trials (RCTs)...
  87. ncbi The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study
    M Stewart
    Cancer Research UK Tumour Pathology Group, Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK
    Histopathology 43:33-9. 2003
    ..The aim of this study was to raise and characterize antibodies against phosphorylated KDR which could be used for studies on human tissues to assess KDR activation and novel inhibitors of KDR activation in clinical trials...
  88. doi New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation
    P Swietach
    Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
    Oncogene 29:6509-21. 2010
    ..This is now an important avenue for further investigation. The importance of CAIX in regulating tumour pH highlights the protein as a potential target for cancer therapy...
  89. ncbi Gene therapy targeting to tumor endothelium
    M Bazan-Peregrino
    Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Woodstock Road, Oxford, UK
    Cancer Gene Ther 14:117-27. 2007
    ..We also overview some of the strategies that have been developed to date and highlight the most promising areas of research...
  90. pmc Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR
    S Gal
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK
    Br J Cancer 90:1211-5. 2004
    ..The overall survival of patients with serum DNA concentrations >221 ng x ml(-1) was better than patients with serum DNA concentration <or=221 ng ml(-1) (Kaplan-Meier, P=0.028)...